Lee's Pharmaceutical logo

Lee's Pharmaceutical(SEHK) 0950

Market CapHK$641.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)+197%
5 Year-73%
1 Year-44%
1 Month-5%
HK$1.06
-3.21%
-0.04Today
Lee's Pharmaceutical last closing stock price
MetricPriceDate
Last closeHKD 1.092026-10-14
Lee's Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.63%HKD 1.182026-10-07
1 month-5.22%HKD 1.152026-09-14
3 month-1.8%HKD 1.112026-07-16
Year to date-28.29%HKD 1.522025-12-31
1 year-43.52%HKD 1.932025-10-14
3 year-15.5%HKD 1.292023-10-13
5 year-72.54%HKD 3.972021-10-15
Since inception+196.62%HKD 0.372002-07-15

Lee's Pharmaceutical Financials at a Glance

Market Cap

HK$641.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

HK$1.94B

Net Income (TTM)

HK$167.27M

EPS (TTM)

HK$0.20

P/E Ratio

5.36

Dividend

HK$0.06

Beta (Volatility)

-0.06 (Low)

Price

HK$1.06

Volume

161,500

Open

HK$1.09

Previous Close

HK$1.09

Daily Range

HK$1.06 - HK$1.09

52-Week Range

HK$0.99 - HK$2.10

Estimated Earnings Date

Mar 30, 2027

0950 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a Hong Kong-based investment holding company engaged in the development, manufacturing, marketing, and sale of pharmaceutical products. The company focuses on various therapeutic areas, including cardiovascular health, oncology, and rare diseases, serving markets in China, Hong Kong, and internationally.

Products and Services
  • Proprietary and generic products for various medical conditions
  • Licensed-in products for chemotherapy and other health issues
  • Innovative treatments for women's health and pediatrics
Growth Outlook
  • Recent quarterly revenue reached HKD 796.57 million, showing strong demand
  • Trailing twelve months (TTM) revenue of HKD 2.4 billion indicates consistent growth
  • Focus on expanding product portfolio in oncology and rare diseases enhances market position
Financial Highlights
  • Net income for Q2 2026 was HKD 95.01 million, reflecting robust profitability
  • TTM dividend yield stands at 5.32%, appealing for income-focused investors
  • Current ratio of 1.06 suggests solid liquidity and financial health
Lee's Pharmaceutical Holdings Limited has established itself as a key player in the pharmaceutical industry, with a diverse product range that addresses critical health issues. The company's recent financial performance demonstrates its ability to generate substantial revenue and maintain profitability, making it an attractive option for potential investors. The focus on expanding its product offerings, particularly in high-demand therapeutic areas, positions the company for continued growth in the evolving healthcare landscape.
AI Generated • Oct 14, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1,094

CEO

Wanee Leelalertsuphakun

Website

www.leespharm.com

Headquarters

Hong Kong, HK

0950 Financials

Key Financial Metrics (TTM)

Gross Margin

53.75%

Operating Margin

-0.40%

Net Income Margin

8.64%

Return on Equity

8.02%

Return on Capital

3.65%

Return on Assets

4.80%

Earnings Yield

18.66%

Dividend Yield

5.32%

Payout Ratio

23.76%

Stock Overview

Market Cap

HK$641.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

588.84M

Volume

161.50K

Avg. Volume

626.15K

Financials (TTM)

Gross Profit

HK$1.04B

Operating Income

-HK$7.79M

EBITDA

HK$283.46M

Operating Cash Flow

HK$577.42M

Capital Expenditure

-HK$164.16M

Free Cash Flow

HK$413.26M

Cash & ST Invst.

HK$364.39M

Total Debt

HK$249.84M

Lee's Pharmaceutical Performance Analysis

Lee's Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31HKD 1,233,148,000-2.6%
20232023-12-31HKD 1,053,034,000-14.6%
20242024-12-31HKD 1,399,969,00032.9%
20252025-12-31HKD 1,435,980,0002.6%
Lee's Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.7%
Q42025-12-31N/A
Q12026-03-317.5%
Q22026-06-30100.0%
Lee's Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31HKD 0.09-97.4%
20232023-12-31HKD 0.03-67.4%
20242024-12-31HKD 0.16456.7%
20252025-12-31HKD 0.16-1.3%
Lee's Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-63.2%
Q42025-12-31N/A
Q12026-03-31284.3%
Q22026-06-3098.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

HK$796.57M

+129.3%

Gross Profit

HK$447.45M

+148.5%

Gross Margin

56.17%

N/A

Market Cap

HK$641.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$586.68K

N/A

Employees

1,094

N/A

Net Income

HK$95.01M

+182.8%

EBITDA

HK$23.61M

-65.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

HK$364.39M

+20.0%

Total Debt

HK$249.84M

+2.6%

Accounts Receivable

HK$216.10M

+16.3%

Inventory

HK$420.99M

+48.9%

Long Term Debt

HK$79.78M

-8.4%

Short Term Debt

HK$170.06M

+8.7%

Return on Assets

4.80%

N/A

Return on Invested Capital

-0.33%

N/A

Free Cash Flow

HK$181.81M

+108.5%

Operating Cash Flow

HK$234.56M

+154.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About 0950

What is the current price of Lee's Pharmaceutical?

Lee's Pharmaceutical is trading at HK$1.06 per share.

What is the 52-week range for Lee's Pharmaceutical?

Over the past 52 weeks, Lee's Pharmaceutical has traded between HK$0.99 and HK$2.10.

How much debt does Lee's Pharmaceutical have?

As of the most recent reporting period, Lee's Pharmaceutical reported total debt of HK$310.27M.

How much cash does Lee's Pharmaceutical have on hand?

Lee's Pharmaceutical reported HK$349.90M in cash and cash equivalents in its most recent financial results.

What is Lee's Pharmaceutical’s dividend yield?

Lee's Pharmaceutical currently has a dividend yield of 5.32%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services